Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease

Status Completed

Clinical Trial Summary

Bone marrow MSCs will be isolated from allogenic donors, expanded under hypoxic conditions using medium containing no serum or animal-derived reagents, and applies for Phase Ⅰ/Ⅱ study in treating 18 recipients with ischemic limb diseases.

Clinical Trial Description

Ischemic limb disease remains one of the major causes of morbidity and mortality in the industrialized world despite the development of several new therapeutic modalities. Based on experimental data demonstrating that infusion or injection of stem/progenitor cells enhances blood flow in models of cardiovascular diseases, clinical trials were initiated in 2001 to treat patients with critical limb ischemia or cardiac ischemia with circulating blood or bone marrow-derived cells. Despite all promises, pending uncertainties and practical limitations attenuate the therapeutic use of stem/progenitor cells for ischemic limb disease. The main theme and method in the current program project, based on expertise, track record, and preliminary results of PI's laboratory, is to focus on clinical studies of using allogenic mesenchymal stem cells (MSCs), expanded under hypoxic conditions (1% O2), in treating ischemic limbs. This project is an integrated and coordinated effort aimed to overcome the regulation of cell product, and the barriers of preclinical and clinical studies. For the purposes, we have specially set up the core laboratory for stem/progenitor cells production and quality control in Cell Therapy Clean Room on the 9th floor of Medical Science Technology Building in Taipei Veterans General Hospital. We have also completed the preclinical studies in using allogenic hypoxic mouse MSCs in treating limb ischemia. In the current project, bone marrow MSCs will be isolated from allogenic donors, expanded under hypoxic conditions using medium containing no serum or animal-derived reagents, and applies for Phase Ⅰ/Ⅱ study in treating 18 recipients with ischemic limb diseases in three years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02336646
Study type	Interventional
Source	Taiwan Bio Therapeutics Co., Ltd.
Contact
Status	Completed
Phase	Phase 1
Start date	May 1, 2015
Completion date	December 20, 2018

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03987061` - MOTIV Bioresorbable Scaffold in BTK Artery Disease	N/A
Recruiting	`NCT03668353` - Recombinant SeV-hFGF2/dF Injection for PAOD	Phase 1
Recruiting	`NCT04110964` - Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT	Phase 1
Not yet recruiting	`NCT03994666` - Cell Therapy in Critical Limb Ischemia	Phase 2
Recruiting	`NCT02389023` - Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery	N/A
Not yet recruiting	`NCT02498080` - Drug Eluting Balloons PTA in Infra-popliteal Arteries in Patients With Critical Limb Ischemia	N/A
Completed	`NCT02539940` - Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
Recruiting	`NCT02239419` - Evaluation of Carbothera in the Treatment of Foot Ulcers	N/A
Recruiting	`NCT01938872` - Evaluating the Effectiveness of Paclitaxel-eluting Balloons for Below-the-knee Angioplasty in Patients With Critical Limb Ischemia	N/A
Active, not recruiting	`NCT01211925` - Distal Venous Arterialisation of Ischemic Limb	Phase 2/Phase 3
Completed	`NCT02454231` - Monocentric Trial: Stem Cell Emergency Life Threatening Limbs Arteriopathy (SCELTA)	Phase 2/Phase 3
Completed	`NCT01758874` - Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia	Phase 2
Completed	`NCT02475200` - Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems
Recruiting	`NCT04583436` - Efficacy and Safety Comparison of the Open and Endovascular Surgical Methods for the Treatment of Long Atherosclerotic Lesions of the Femoral-popliteal Segment Below the Knee, TASC D in Patients With Critical Limb Ischemia	N/A
Completed	`NCT04071782` - Investigating the Safety and Efficacy of the Treatment With the Selution Sirolimus Coated Balloon in TASC C and D Tibial Occlusive Disease in Patients With Critical Limb Ischemia From Singapore	N/A
Completed	`NCT03669458` - Feasibility Clinical Trial Using the SPUR System to Demonstrate Safety and Efficacy.	N/A
Not yet recruiting	`NCT06007469` - Pedal Acceleration Time (PAT) as a Measure of Foot Perfusion
Recruiting	`NCT04110327` - An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease
Completed	`NCT02260622` - Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia	Phase 2
Recruiting	`NCT02054416` - External Compression Therapy for Secondary Prevention of Lower-Limb Loss and Cardiovascular Mortality	N/A